A healthcare infrastructure company

The connective tissue of precision oncology.

Lab Angelus builds the digital infrastructure that connects community pathology, molecular reference laboratories, and treating oncologists — so that every cancer patient benefits from precision medicine as it was designed.

/ 01

A platform layer

Today: LabDispatch — the digital coordination platform connecting community pathology with the nation's leading molecular reference laboratories.

/ 02

A data foundation

Tomorrow: a longitudinal oncology dataset captured at the moment of diagnostic decision-making — earlier and richer than EHR aggregation can provide.

/ 03

A compliance posture

Always: architected from inception for HIPAA, the Anti-Kickback Statute Personal Services Safe Harbor, and the SOC 2 controls expected of mature healthcare infrastructure.

"
Cancer care depends on what happens between the labs. We are what happens between them.
— The Lab Angelus working principle
Leadership

The people behind the platform.

Lab Angelus is built by people who have spent careers inside the laboratory and at the table where healthcare policy is written. The combination matters: a platform for this industry has to survive both technical and regulatory scrutiny, and ours does.

Our flagship platform

LabDispatch.

LabDispatch is the digital coordination platform connecting community pathology laboratories with the nation's leading molecular reference laboratories — bringing precision oncology testing into a single, traceable workflow. It is the first product from Lab Angelus and the proof of the larger thesis.

LabDispatch
Governance & backing

Backed by leading practitioners in oncology and pathology.

Build with us.

Lab Angelus partners with reference laboratories, pathology networks, oncology practices, and the institutions advancing precision medicine. We respond to every serious inquiry within one business day.

The company

Why Lab Angelus exists.

Precision oncology is only as good as the workflow that delivers it. Across the United States, two million patients are diagnosed with cancer each year, and a majority of those eligible for molecular profiling do not receive it — not because the science is missing, but because the coordination is.

Mission

What we do.

Lab Angelus builds the connective tissue of precision oncology. We coordinate the laboratories, the clinicians, and the data on which modern cancer care depends — quietly, compliantly, and at the scale precision medicine actually requires.

Vision

Where we are going.

A future where the workflow no longer determines the outcome — where every cancer patient receives the precise diagnosis, the right treatment, and the coordinated care that precision oncology was designed to deliver.

The moment

Precision oncology has arrived. The plumbing has not.

In the last two decades, the science of cancer treatment has been transformed. Molecular profiling now identifies the precise mutations driving an individual patient's disease, and targeted therapies and immunotherapies developed against those mutations now offer responses that earlier generations of oncologists could not have imagined.

And yet, in 2026, the majority of cancer patients in the United States never receive the complete molecular workup that would qualify them for those therapies. The reason is not scientific. It is operational. The diagnostic specimens that should travel from a community pathologist's microscope to a molecular reference laboratory's sequencer pass through a workflow that was never designed for them — a workflow of phone calls, faxed requisitions, ten different lab portals, and email chains that lose specimens, lose results, and lose patients to the gap between diagnosis and treatment.

Lab Angelus exists to close that gap. We are building the platform layer on which the next era of precision oncology will run. Not a tool. Not a product. Infrastructure — the kind that is invisible when it works and indispensable once it does.

That infrastructure begins with LabDispatch, our flagship platform for cancer specimen logistics. It extends, over time, into a longitudinal oncology dataset captured at the moment of diagnostic decision-making. And it is designed, every step of the way, around the principle that healthcare infrastructure must satisfy the regulators, the lawyers, the patients, and the practitioners — all of them, on day one.

How we work

Operating principles.

The decisions we make today determine what we are able to do five and ten years from now. These principles are how we make them.

/ 01

Compliance is the foundation.

Anti-Kickback Statute Safe Harbor, HIPAA, SOC 2, and FMV determinations are not late-stage retrofits. They are architectural decisions we made on day one — because healthcare infrastructure has to survive scrutiny from the regulators, the lawyers, and the buyers of every counterparty we serve.

/ 02

Pathology is at the table.

Lab Angelus was co-founded by a practicing molecular pathologist and continues to be guided by the daily realities of community pathology practice. The platform is built by people who know the laboratory because they have lived in it.

/ 03

Infrastructure, not theater.

We optimize for what is durable over what is dramatic. Our work shows up in turnaround times, in audit logs, in compliant payments, and in the absence of dropped specimens — not in conference keynotes.

/ 04

Patient outcomes are the only scorecard.

Every operational decision is evaluated against a single question: does it help more cancer patients receive the precise diagnosis and the right treatment, faster? When the answer is no, we revise.

Where this goes next.

If your laboratory, your practice, or your organization sees what we see — that the workflow has been the problem, and that the workflow can be fixed — we want to talk.

Leadership

A practitioner. An executive. A shared standard.

Lab Angelus is led by Samuel K. Caughron, MD — Co-Founder and Managing Principal, and one of the country's most active voices in community molecular pathology — and Ryan H. McCarty, JD, LL.M., MBA, Chief Executive Officer. Together they bring the medical depth and the executive discipline that healthcare infrastructure requires.

Ryan H. McCarty
Chief Executive Officer

Ryan H. McCarty

JD · LL.M. (Health Law) · MBA

Ryan McCarty serves as Chief Executive Officer of Lab Angelus. He is also the founder of Becket More, a Kansas City–based business and legal consulting firm whose healthcare practice has advised Mercy St. Louis, the University of Kansas Health System, MAWD Pathology Group, and other major regional providers across nearly a decade of engagements.

A graduate of Washington University in St. Louis (BA, 2004), Mr. McCarty served four years on active duty in the United States Air Force in thermonuclear ICBM operations and four years in the reserves, holding Top Secret SCI clearance. He earned his JD from the University of Kansas School of Law in 2010, clerking for the U.S. Attorney's Office for the Western District of Missouri. He subsequently completed an MBA from Washington University (with honors, 2016) and an LL.M. in Health Law from Saint Louis University (2016).

Mr. McCarty's legal career spans federal and state prosecution, medical malpractice defense, administrative law, and governmental affairs. He is a member of the American College of Healthcare Executives, the American Health Law Association, and multiple bar associations, and has served on the boards of several businesses and nonprofits.

Samuel K. Caughron, MD
Co-Founder & Managing Principal

Samuel K. Caughron, MD, FCAP

Anatomic & Clinical Pathology · Molecular Genetic Pathology

Samuel K. Caughron is Co-Founder and Managing Principal of Lab Angelus. He also serves as Chief Strategy Officer of MAWD Pathology Group — the largest provider of pathology and laboratory professional services in the Kansas City region — and as Medical Director of AdventHealth Shawnee Mission.

A native of Kansas City, Dr. Caughron received his medical degree and Anatomic and Clinical Pathology training at Creighton University, then completed a fellowship in Molecular Genetic Pathology at Vanderbilt University. He became the region's first board-certified Molecular Genetic Pathologist and founded two community-based molecular diagnostics laboratories — first in Billings, Montana, then at MAWD, where he established the MAWD Molecular Lab in 2010. He is nationally recognized for bringing advanced molecular testing to community cancer patients.

Dr. Caughron serves as Vice President of the Independent Pathology Practice Network, Vice-Chair of the College of American Pathologists' Personalized Healthcare Committee, Chair of the Association for Molecular Pathology's Economic Affairs Committee, and on the Board of the American Pathology Foundation. He is board-certified by the American Board of Pathology in Anatomic and Clinical Pathology and Molecular Genetic Pathology.

Governance & backing

Backed by leading practitioners in oncology and pathology.

Reach the office of the CEO.

Strategic, partnership, and counsel inquiries are received directly by Mr. McCarty's office. Substantive responses follow within a business day.

The platform

A platform built first. A data foundation built always.

Lab Angelus develops the platform layer for precision oncology. Our flagship product, LabDispatch, is in active deployment with community pathology practices and the nation's leading molecular reference laboratories. Behind it sits the foundation of what comes next.

Track 01 — Today

LabDispatch.

The digital coordination platform connecting community pathology, molecular reference laboratories, and treating oncologists. Live commercial deployment is underway with a publicly traded molecular diagnostics partner — a category leader in cancer reference testing.

LabDispatch is available through the Independent Pathology Practice Network and is being introduced to adjacent networks, including academic medical center laboratories, through the same compliance-first model.

Track 02 — Tomorrow

The diagnostic decision layer.

LabDispatch captures something no electronic health record aggregator can: the moment of diagnostic decision-making — what tests were considered, what was ordered, what was rejected, and why. Over time, this becomes one of the most consequential longitudinal oncology datasets in the United States.

That dataset, used responsibly and de-identified rigorously, can accelerate clinical trial recruitment, inform real-world evidence for regulatory submissions, and surface the diagnostic disparities that no one currently sees — because no one currently measures them.

Posture

Why this works.

Several conditions had to be true for a platform like this to exist. They are true now — and Lab Angelus is positioned to build it.

/ 01

The market is ready.

Precision oncology has crossed from research curiosity to standard of care. Molecular testing penetration is growing at double-digit rates annually, and reference labs face escalating customer acquisition costs in a fragmented community pathology landscape.

/ 02

The network is ours.

Founder relationships with the Independent Pathology Practice Network and the academic GOAL consortium provide structural access to the source labs and the destination labs that the platform connects. This is not a cold-call business.

/ 03

The architecture is compliant.

The Anti-Kickback Statute Personal Services Safe Harbor, HIPAA Business Associate framework, and SOC 2 controls were design assumptions from the first line of code. Reference labs' compliance counsel recognize the structure immediately.

/ 04

The interoperability is solved.

The platform implements HL7 FHIR resources for orders, specimens, and reports, and integrates with the major electronic health record and laboratory information systems that community practices already operate.

See LabDispatch.

The platform site has more on how it works for pathologists, reference labs, and oncologists — including the security and compliance posture.

Governance

Compliance was not added later. It was the foundation.

Healthcare infrastructure is judged by what happens when a regulator, an auditor, or in-house counsel actually looks. Lab Angelus is built around the working assumption that all three will — and that the answers should already be in place when they do.

HIPAA

Business Associate posture

Lab Angelus operates as a HIPAA Business Associate with every participating laboratory and clinical practice. Business Associate Agreements are in place, technical safeguards are aligned with the Security Rule, and audit logging covers every data event.

AKS

Personal Services Safe Harbor

Fee structures across the platform are documented to satisfy the Anti-Kickback Statute Personal Services and Management Contracts Safe Harbor — including written agreements, set-in-advance compensation, fair market value pricing, and arm's-length structuring.

SOC 2

Type II readiness

The platform's security controls are designed against the SOC 2 Trust Services Criteria — security, availability, confidentiality, and processing integrity. Type II audit is on the production roadmap.

FMV

Independent FMV determinations

Every fee category — setup, license, per-specimen — is supported by an independent fair market value determination from a recognized healthcare valuation firm. Determinations are refreshed on a defined cadence.

COI

Conflict of interest policy

Lab Angelus maintains a written conflict of interest policy with mandatory recusal procedures for any decision implicating personnel with ownership interests in participating laboratories.

FHIR

Interoperability standards

The platform implements HL7 FHIR resources for orders, specimens, and reports. Integration with major EHR and LIS systems is a design assumption, not a special case.

Counsel

The people who review our work.

Lab Angelus's compliance architecture is reviewed and documented by outside counsel with deep laboratory and pathology law expertise. Healthcare counsel is engaged on an ongoing basis to keep pace with the regulatory environment in which the platform operates.

  • Health law counsel: Randal Schultz · Lathrop GPM
  • Independent FMV: Engaged with recognized healthcare valuation specialists
  • Exclusion screening: OIG List of Excluded Individuals/Entities and SAM debarment screening on every participant
Practice

How compliance shows up in our day.

Compliance posture is not a static document. These are the routine operating practices that keep the architecture intact as the business grows.

/ 01

FMV determinations are independent and refreshed.

Lab Angelus does not set its own fair market values. Independent third-party determinations are obtained for every fee category at platform inception and renewed on a defined cadence, with methodology documented and made available to compliance reviewers on request.

/ 02

Source labs pay their own costs.

Platform license and setup fees flow from source labs directly — not from destination labs on their behalf. This structural choice removes the most common AKS exposure that platforms in adjacent categories have failed to anticipate.

/ 03

Co-founder interests are governed, not hidden.

The Lab Angelus governance model explicitly contemplates that pathologist founders may also have ownership interests in participating laboratories. The conflict of interest policy and recusal procedures address this transparently and consistently.

/ 04

De-identification is taken seriously.

If and when data analytics become a meaningful product line, de-identification will follow the HIPAA Safe Harbor methodology with an independent expert determination on file. There is no shortcut path here, and we will not invent one.

For counsel and compliance officers.

Qualified counsel may request the platform's full compliance package, including the AKS framework, the FMV methodology, the BAA template, and the conflict of interest policy.

Contact

A direct line to the company.

Lab Angelus reads every legitimate inbound and responds within one business day. Partnership inquiries, counsel inquiries, journalist inquiries, and inquiries from prospective collaborators in oncology, pathology, and healthcare technology are all welcome here.

We will not share your information with third parties.